arrow
J

Julie Sanchez

national institutes of health
H指数:14
被引数:1,060

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The structure of the dopamine D3 receptor bound to cariprazine reveals principles for partial agonists with designed pharmacology

多巴胺D3受体与卡利拉赞结合的结构揭示了具有设计药理学特性的部分激动剂的原则

2026-08-280
OA
Dual-target mu opioid-dopamine D3 receptor (MOR-D3R) ligands based on etonitazene: New leads for transforming nitazenes into novel analgesics

基于依诺硝唑的双靶点μ阿片-多巴胺D3受体(MOR-D3R)配体:将硝唑类化合物转化为新型镇痛药的新先导化合物

2026-06-010
OAAI
Discovery of the First-in-Class Inhibitors of Hypoxia Up-Regulated Protein 1 (HYOU1) Suppressing Pathogenic Fibroblast Activation
2024-02-260
PRE
Pharmacological and Physicochemical Properties Optimization for Dual-Target Dopamine D3 (D3R) and μ-Opioid (MOR) Receptor Ligands as Potentially Safer Analgesics

双靶点多巴胺D3 (D3R) 和 μ-阿片 (MOR) 受体配体作为潜在更安全的镇痛药的药理和理化性质优化

2023-07-196
OA
Dopamine D3/D2 Receptor Ligands Based on Cariprazine for the Treatment of Psychostimulant Use Disorders That May Be Dual Diagnosed with Affective Disorders

基于Cariprazine的多巴胺D3/D2受体配体用于治疗可能被双重诊断为情感障碍的精神兴奋剂使用障碍

2023-01-203
OA
Novel Dual-Target μ-Opioid Receptor and Dopamine D3 Receptor Ligands as Potential Nonaddictive Pharmacotherapeutics for Pain Management

新型双靶点 μ-阿片受体和多巴胺D3受体配体作为疼痛治疗的潜在非成瘾性药物治疗

2021-05-2018
OAAI
Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists
2020-03-31227
OA
Discovery of Acylsulfonohydrazide-Derived Inhibitors of the Lysine Acetyltransferase, KAT6A, as Potent Senescence-Inducing Anti-Cancer Agents

发现赖氨酸乙酰转移酶的酰基磺酰肼衍生抑制剂KAT6A作为有效的衰老诱导抗癌剂

2020-03-0214
PREAI
Discovery of Benzoylsulfonohydrazides as Potent Inhibitors of the Histone Acetyltransferase KAT6A
2019-06-2925
PREAI